PARP inhibitors and breast cancer: highlights and hang-ups
Collections
Subject
Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
Breast cancer
PARP inhibitors
BRCA1
BRCA2
treatment
synthetic lethality
CELL-FREE DNA
BRCA2 REVERSION MUTATIONS
SENSITIVE OVARIAN-CANCER
POLY(ADP-RIBOSE) POLYMERASE
HOMOLOGOUS RECOMBINATION
MAINTENANCE THERAPY
DOUBLE-BLIND
PHASE-II
SECONDARY MUTATIONS
REPAIR DEFECTS
Research team
Gene Function
Language
eng
Date accepted
2018-02-02
License start date
2018-01-01
Citation
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (2), pp. 83 - 94 (12)
Publisher
TAYLOR & FRANCIS LTD